Early interneuron problems in Huntington's disease
Interneurons as Early Drivers of Huntington´s Disease Progression
This project looks at whether early problems with specific brain cells called interneurons cause Huntington's disease and whether fixing those problems early can prevent or reduce symptoms for people with the HD gene.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-11141636 on NIH RePORTER |
What this research studies
From my view as a patient, researchers are studying how a type of brain cell called an interneuron develops in Huntington's disease using genetically modified mouse models and tissue analyses. They map how missing or abnormal interneurons change connections between the cortex and the striatum and make the brain overactive. The team uses genetic 'rescue' experiments to restore interneuron development in mice and then measures circuit function, cell survival, and behavior to see if that improves outcomes. If early fixes reduce later brain damage in these models, the findings could point to new targets for treatments aimed at prevention or slowing of HD.
Who could benefit from this research
Good fit: People who carry the Huntington's disease gene mutation (pre-manifest or symptomatic adults) would be the group most likely to benefit from interventions derived from this research.
Not a fit: People without the HD mutation or those in very advanced stages of HD driven primarily by later-stage degeneration may be less likely to benefit from early-development-focused approaches.
Why it matters
Potential benefit: If successful, this work could identify new early targets for therapies that prevent or slow the development of Huntington's symptoms.
How similar studies have performed: Previous studies have reported interneuron deficits in HD and early genetic rescue in animal models shows promise, but translating these findings to human treatments is largely untested.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Mehler, Mark F — Albert Einstein College of Medicine
- Study coordinator: Mehler, Mark F
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.